Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Succinylcholine is a depolarizing neuromuscular blocking agent used primarily as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation. It acts by binding to post-synaptic cholinergic receptors at the motor endplate of skeletal muscle, causing persistent depolarization and subsequent paralysis. Its onset is rapid (within 60 seconds IV) and duration short (4–6 minutes). Succinylcholine does not affect consciousness or pain perception and must be administered with adequate anesthesia. It is rapidly hydrolyzed by plasma butyrylcholinesterase. The drug is also used in emergency medicine for rapid sequence intubation due to its fast onset and brief action[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on succinylcholine.